(Q35641640)

9 August 2017

1 reference

title

Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection (English)

1 reference

9 August 2017

1 reference

Roula B Qaqish

1

1 reference

9 August 2017

Keri A Mattes

series ordinal

2

1 reference

9 August 2017

David J Ritchie

series ordinal

3

1 reference

9 August 2017

1 December 2003

1 reference

9 August 2017

Clinical Therapeutics

1 reference

9 August 2017

25

1 reference

9 August 2017

12

1 reference

9 August 2017

3084-3099

1 reference

Update on chronic viral hepatitis

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Management of viral hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Chronic hepatitis B: current and future treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Suppressing hepatitis B without resistance--so far, so good

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990093-2

7 January 2021

10.1016/S0149-2918(03)90093-2

Identifiers

DOI

1 reference

release_khmglug6obfexfadkol7eghh2y

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/khmglug6obfexfadkol7eghh2y

24 November 2022

mapped directly with Wikidata item

1 reference